MedTrace Logo

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

NCT00192673 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2009-09-30

No results posted yet for this study

Summary

The purpose of this study is

1. to determine the correct dose for intramuscular administration
2. to compare the frequency of antibody formation after intramuscular administration of native E.coli asparaginase and PEG-asparaginase during two treatment courses in the treatment of childhood lymphoblastic leukemia

Conditions

Interventions

DRUG

PEG-asparaginase

Sponsors & Collaborators

  • Medac, Hamburg, Germany

    collaborator UNKNOWN

  • Danish Child Cancer Foundation

    collaborator OTHER

  • Nordic Society for Pediatric Hematology and Oncology

    lead OTHER

Principal Investigators

  • Henrik Schrøder, M.D. PhD · Department of Pediatrics, Skejby Hospital, Denmark and member of the Scientific Commmittee in NOPHO

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Completion
2013-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00192673 on ClinicalTrials.gov